COVID-19 Pathophysiology and Proresolving Therapies in Cystic Fibrosis

Project

Overview
Research

Contributor (3)

RECCHIUTI ANTONIO Scientific Manager

MATTOSCIO DOMENICO Participant

MUCCI MATTEO Participant

Leading department

DIPARTIMENTO DI SCIENZE MEDICHE, ORALI E BIOTECNOLOGICHE Principale

Term type

Programmi NIH e altri Enti USA

Financier

CYSTIC FIBROSIS FOUNDATION

Funding Organization

Partner

Università degli Studi G.D'Annunzio di CHIETI

Total Contribution (assigned) University (EUR)

215,780€

Date/time interval

January 1, 2021 - December 31, 2022

Project duration

24 months

Concepts (14)

ERC field

LS6_1 - Innate immunity - (2022)

LS6_11 - Innovative immunological tools and approaches, including therapies - (2022)

LS6_3 - Regulation of the immune response - (2022)

LS6_4 - Immune-related diseases - (2022)

LS6_5 - Biology of pathogens (e.g. bacteria, viruses, parasites, fungi) - (2022)

LS6_6 - Infectious diseases - (2022)

LS6_7 - Mechanisms of infection - (2022)

LS6_8 - Biological basis of prevention and treatment of infection - (2022)

LS7_10 - Preventative and prognostic medicine - (2022)

LS7_5 - Applied gene, cell and immune therapies - (2022)

LS7_7 - Pharmacology and toxicology - (2022)

LS7_8 - Effectiveness of interventions, including resistance to therapies - (2022)

Sustainable Development Goals

Goal 3: Good health and well-being

Academic field (2000 version)

Settore MED/05 - Patologia Clinica

Free text keywords (3)

Risoluzione dell'infiammazione

inflammation

malattie infettive

No Results Found